================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) June 4, 2007
------------------------------
Pharmion Corporation
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-50447 84-1521333
------------------------------- ---------------------- -----------------------
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
2525 28th Street, Boulder, Colorado 80301
---------------------------------------------------- ---------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 720-564-9100
----------------------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
Item 8.01 Other Events.
----
On June 4, 2007, Pharmion Corporation (the "Company")
announced clinical data from various studies investigating
the Company's marketed and pipeline products as presented at
the American Society of Clinical Oncology's 43rd Annual
Meeting.
The press releases are filed as Exhibits 99.1 and 99.2 to
this Form 8-K and are incorporated herein by reference in
their entirety.
Item 9.01 Financial Statements and Exhibits.
----
(d) Exhibits
99.1 Press Release issued by Pharmion Corporation on
June 4, 2007 announcing Additional New Data from
Satraplatin SPARC Phase 3 Investigational Trial.
99.2 Press Release issued by Pharmion Corporation on
June 4, 2007 announcing Amrubicin Shows
Encouraging Results Compared to Standard of Care
in Second Line Treatment of Small Cell Lung
Cancer.
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMION CORPORATION
Date: June 4, 2007 By: /s/ Steven N. Dupont
------------------------------------------
Name: Steven N. Dupont
Title: Vice President and General Counsel
- 3 -